ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2226

Accelerated Aging Based on Blood DNA Methylation in SLE Participants Compared to Healthy Controls

Joanne Nitithalm1, Olivia Solomon2, Laura Trupin3, Patricia Katz4, Jinoos Yazdany4, Maria Dall'Era5, Lisa F Barcellos2, Lindsey Criswell6 and Cristina M Lanata7, 1NIH/NHGRI, Bethesda, MD, 2University of California, Berkeley, Berkeley, CA, 3UC San Francisco, San Francisco, CA, 4UCSF, San Rafael, CA, 5University of California, Division of Rheumatology, San Francisco, CA, 6National Human Genome Research Institute, NIH, Bethesda, MD, 7NIH/NHGRI, Washington, DC

Meeting: ACR Convergence 2022

Keywords: Aging, Epigenetics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Epigenetic clocks based on DNA methylation in blood have been shown to correlate with biological aging and predict adverse health outcomes, including mortality. Accelerated aging based on the epigenetic clock is defined as having a higher predicted biological age than chronological age. The aim of this study is to determine whether SLE patients have accelerated aging compared to healthy controls.

Methods: DNA methylation data were generated using the Illumina Infinium Human MethylationEPIC BeadChip from whole blood samples in a multi-ethnic cohort of 323 SLE cases and 99 healthy controls. Background correction with dye-bias normalization using the preprocessNoob function in the minfi R package was performed on the methylation data. The methylClock R package was used to estimate the biological age using the DNAm Pheno Age clock. The DNAm Pheno Age uses 513 CpGs to estimate the biological age. To test for association with age acceleration in SLE patients versus controls, DNAm Pheno Age was regressed on chronological age, SLE, female, batch and race/ethnicity. Separate models were also run for association testing of income and education. DNAm Pheno Age was regressed on chronological age, income or education, female, batch and race/ethnicity. Additionally, among SLE patients only, association testing was run in separate models for anti-DsDNA status, presence of lupus nephritis and the SLE severity index by adjusting for chronological age, female, batch and race/ethnicity.

Results: Accelerated aging was associated with SLE status (βSLE=6.3, p=1.85E-14), adjusting for chronological age, sex race/ethnicity and batch. Among SLE patients, accelerated age was associated with anti-dsDNA status (βanti-dsDNA=3.19, p=0.0002), lupus nephritis (βLN=2.48, p=0.0019) and SLE severity index (βsevere=1.10, p=1.09E-05). Accelerated aging was associated with income less than $40,000 (βincome=3.32, p=1.73E-05) but association with education level at high school approached significance.

Conclusion: SLE is associated with accelerated age using DNAm Pheno Age to estimate biological age. Among SLE cases, an association is observed between accelerated age and presence of lupus nephritis, anti-dsDNA positivity, and SLE severity. Sociodemographic factors such as poverty can also influence accelerated aging.

Supporting image 1

Supporting image 2


Disclosures: J. Nitithalm, None; O. Solomon, None; L. Trupin, None; P. Katz, None; J. Yazdany, AstraZeneca, AstraZeneca, Bristol-Myers Squibb(BMS), Gilead, Pfizer, Aurinia; M. Dall'Era, GlaxoSmithKline (GSK), AstraZeneca, Aurinia, BMS, Amgen; L. Barcellos, None; L. Criswell, None; C. M Lanata, None.

To cite this abstract in AMA style:

Nitithalm J, Solomon O, Trupin L, Katz P, Yazdany J, Dall'Era M, Barcellos L, Criswell L, M Lanata C. Accelerated Aging Based on Blood DNA Methylation in SLE Participants Compared to Healthy Controls [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/accelerated-aging-based-on-blood-dna-methylation-in-sle-participants-compared-to-healthy-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/accelerated-aging-based-on-blood-dna-methylation-in-sle-participants-compared-to-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology